High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response

Circulation

Volumn 114, Issue SUPPL. 1, 2006, Pages

  Boodhwani, Munir ^b   Nakai, Yasunari ^b   Voisine, Pierre ^b   Feng, Jun ^b   Li, Jian ^a   Mieno, Shigetoshi ^b   Ramlawi, Basel ^b   Bianchi, Cesario ^b   Laham, Roger ^a   Sellke, Frank W ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b LMOB 2A ^*

Author keywords

Angiogenesis; Endothelium; HMG CoA reductase inhibitors; Hypercholesterolemia; Ischemia

Indexed keywords

ADENOSINE DIPHOSPHATE; ANGIOGENIC PROTEIN; ATORVASTATIN; ENDOSTATIN; PROTEIN KINASE B; VASCULOTROPIN; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ANGIOPOIETIN RECEPTOR; ANGIOSTATIN; APOPTOSIS INDUCING FACTOR; CASPASE; CASPASE 3; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PROTEIN BCL 2; PYRROLE DERIVATIVE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CHOLESTEROL DIET; COLLATERAL CIRCULATION; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; DRUG DOSE REGIMEN; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEEDING; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HYPERCHOLESTEROLEMIA; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SWINE; ANIMAL; APOPTOSIS; ARTERIOLE; BIOSYNTHESIS; BLOOD; CORONARY ARTERY BLOOD FLOW; CORONARY BLOOD VESSEL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MINIPIG; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; VASCULAR ENDOTHELIUM; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENOSINE DIPHOSPHATE; ANGIOSTATINS; ANIMALS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; ARTERIOLES; CASPASE 3; CASPASES; CHOLESTEROL; CORONARY CIRCULATION; CORONARY VESSELS; DRUG EVALUATION, PRECLINICAL; ENDOSTATINS; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MATRIX METALLOPROTEINASE 9; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; NITROPRUSSIDE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; RECEPTOR, TIE-2; SWINE; SWINE, MINIATURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATION;

EID: 33747173757     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.000356     Document Type: Article

References (30)

1. Tofukuji M, Metais C, Li J, Franklin A, Simons M, Sellke FW. Myocardial VEGF expression after cardiopulmonary bypass and cardioplegia. Circulation. 1998;98:II242-II246; discussion II247-II248.
2. Sellke FW, Wang SY, Stamler A, Lopez JJ, Li J, Simons M. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol. 1996;271:H713-H720.
3. Metais C, Li J, Simons M, Sellke FW. Effects of coronary artery disease on expression and microvascular response to VEGF. Am J Physiol. 1998;275:H1411-H1418.
4. Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK, Laham RJ, Li W, Pike M, Sellke FW, Stegmann TJ, Udelson JE, Rosengart TK. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation. 2000;102:E73-E86.
5. Boodhwani M, Nakai Y, Mieno S, Voisine P, Boodhwani M, Bianchi C, Araujo E, Feng J, Michael K, Li J, Sellke FW. Hypercholesterolemia impairs the myocardial angiogenic response in a swine model of chronic ischemia: role of endostatin and oxidative stress. Ann Thorac Surg. 2006;81:634-641.
6. Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, Laham RJ, Sellke FW. Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a swine endothelial dysfunction model. Circulation. 2003; 108(suppl 1):II335-II340.
7. Voisine P, Bianchi C, Ruel M, Malik T, Rosinberg A, Feng J, Khan TA, Xu SH, Sandmeyer J, Laham RJ, Sellke FW. Inhibition of the cardiac angiogenic response to exogenous vascular endothelial growth factor. Surgery. 2004;136:407-415.
8. Balk EM, Karas RH, Jordan HS, Kupelnick B, Chew P, Lau J. Effects of statins on vascular structure and function: a systematic review. Am J Med. 2004;117:775-790.
9. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 2002;90:1243-1250.
10. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation. 2004;109:II34-II41.
11. Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ Res. 2002;90:737-744.
12. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105:739-745.
13. Momose M, Abletshauser C, Neverve J, Nekolla SG, Schnell O, Standl E, Schwaiger M, Bengel FM. Dysregulation of coronary microvascular reactivity in asymptomatic patients with type 2 diabetes mellitus. Eur J Nucl Med Mol Imaging. 2002;29:1675-1679.
14. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation. 1999;99:2239-2242.
15. Voisine P, Bianchi C, Khan TA, Ruel M, Xu SH, Feng J, Li J, Malik T, Rosinberg A, Sellke FW. Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of l-arginine in a porcine model of endothelial dysfunction. J Thorac Cardiovasc Surg. 2005;129:1414-1420.
16. Nishimatsu H, Suzuki E, Satonaka H, Takeda R, Omata M, Fujita T, Nagai R, Kitamura T, Hirata Y. Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats. Am J Physiol. 2005;288:H1770-H1776.
17. Perings SM, Grubert N, Kleinbongard P, Reinecke P, Schulz R, Hermsen D, Willers R, Kelm M. Chronic treatment with fluvastatin improves smooth muscle dilatory function in genetically determined hyperlipoproteinemia. J Cardiovasc Pharmacol. 2004;43:183-190.
18. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
19. Frick M, Dulak J, Cisowski J, Jozkowicz A, Zwick R, Alber H, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis. 2003;170:229-236.
20. Blanco-Colio LM, Villa A, Ortego M, Hernandez-Presa MA, Pascual A, Plaza JJ, Egido J. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis. 2002;161:17-26.
21. Erl W, Hristov M, Neureuter M, Yan ZQ, Hansson GK, Weber PC. HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells. Atherosclerosis. 2003;169:251-258.
22. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404-407.
23. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
24. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, Sukhatme VP. Endostatin induces endothelial cell apoptosis. J Biol Chem. 1999;274:11721-11726.
25. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE. Endostatin's antiangiogenic signaling network. Mol Cell. 2004;13:649-663.
26. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM, Noel A. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 2002;16:1802-1804.
27. Ackah E, Yu J, Zoellner S, Iwakiri Y, Skurk C, Shibata R, Ouchi N, Easton RM, Galasso G, Birnbaum MJ, Walsh K, Sessa WC. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest. 2005;115:2119-2127.
28. Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L, Ogawa W, Del Monte F, Gwathmey JK, Grazette L, Hemmings B, Kass DA, Champion HC, Rosenzweig A. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest. 2005;115:2128-2138.
29. Fuchs S, Baffour R, Zhou YF, Shou M, Pierre A, Tio FO, Weissman NJ, Leon MB, Epstein SE, Kornowski R. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol. 2001;37:1726-1732.
30. Radke PW, Heinl-Green A, Frass OM, Griesenbach U, Ferrari S, Geddes DM, Alton EW. Effects of intramyocardial pVEGF165 delivery on regional myocardial blood flow: evidence for a spatial 'delivery-efficacy' mismatch. Gene Ther. 2004;11:1249-1255.